Sangamo Shares Rally Premarket on License Deal With Astellas

Dow Jones12-19

By Colin Kellaher

Shares of Sangamo Therapeutics rose sharply in premarket trading Thursday after the genetic-medicine company said it inked a potentially lucrative licensing agreement with Japan's Astellas Pharma.

Sangamo said it will receive a $20 million upfront license fee from Astellas and will be eligible to earn up to an additional $1.3 billion in licensed target fees and milestone payments under the agreement, along with royalties on sales of products emerging from the deal.

The Richmond, Calif., company said the agreement gives Astellas a license to use its novel proprietary capsid, STAC-BBB, for one neurological disease target, with the right to add up to four more targets.

Sangamo shares, which closed Wednesday at $2.35, were recently up 23% to $2.90 in premarket trading.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 19, 2024 06:20 ET (11:20 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492258861?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-19 19:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492258861","market":"sg","top_or_hot":-1,"title":"Sangamo Shares Rally Premarket on License Deal With Astellas","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Sangamo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rose sharply in premarket trading Thursday after the genetic-medicine company said it inked a potentially lucrative licensing agreement with Japan's Astellas Pharma. \n</p>\n<p>\n  Sangamo said it will receive a $20 million upfront license fee from Astellas and will be eligible to earn up to an additional $1.3 billion in licensed target fees and milestone payments under the agreement, along with royalties on sales of products emerging from the deal. \n</p>\n<p>\n  The Richmond, Calif., company said the agreement gives Astellas a license to use its novel proprietary capsid, STAC-BBB, for one neurological disease target, with the right to add up to four more targets. \n</p>\n<p>\n  Sangamo shares, which closed Wednesday at $2.35, were recently up 23% to $2.90 in premarket trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 19, 2024 06:20 ET (11:20 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sangamo Shares Rally Premarket on License Deal With Astellas</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSangamo Shares Rally Premarket on License Deal With Astellas\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-19 19:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Colin Kellaher \n\n\n \n\n\n  Shares of Sangamo Therapeutics rose sharply in premarket trading Thursday after the genetic-medicine company said it inked a potentially lucrative licensing agreement with ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4556","symbol_name":"基因编辑","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492258861","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492258861","pubTimestamp":1734607200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Sangamo Therapeutics rose sharply in premarket trading Thursday after the genetic-medicine company said it inked a potentially lucrative licensing agreement with Japan's Astellas Pharma.Sangamo said it will receive a $20 million upfront license fee from Astellas and will be eligible to earn up to an additional $1.3 billion in licensed target fees and milestone payments under the agreement, along with royalties on sales of products emerging from the deal.The Richmond, Calif., company said the agreement gives Astellas a license to use its novel proprietary capsid, STAC-BBB, for one neurological disease target, with the right to add up to four more targets.Sangamo shares, which closed Wednesday at $2.35, were recently up 23% to $2.90 in premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4556":"基因编辑","BK4139":"生物科技","BK4007":"制药","SGMO":"Sangamo Therapeutics Inc","ALPMY":"Astellas Pharma, Inc."},"translate_title":"Sangamo股价因与安斯泰来达成许可协议而盘前上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALPMY":0.9,"SGMO":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Shares of Sangamo Therapeutics rose sharply in premarket trading Thursday after the genetic-medicine company said it inked a potentially lucrative licensing agreement with Japan's Astellas Pharma. \n\n\n  Sangamo said it will receive a $20 million upfront license fee from Astellas and will be eligible to earn up to an additional $1.3 billion in licensed target fees and milestone payments under the agreement, along with royalties on sales of products emerging from the deal. \n\n\n  The Richmond, Calif., company said the agreement gives Astellas a license to use its novel proprietary capsid, STAC-BBB, for one neurological disease target, with the right to add up to four more targets. \n\n\n  Sangamo shares, which closed Wednesday at $2.35, were recently up 23% to $2.90 in premarket trading. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 19, 2024 06:20 ET (11:20 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492258861"}